San Diego-based CoDa Therapeutics Inc., which is developing Nexagon, a topical cream to treat wounds, has garnered $10 million in a Series A financing round.
The funding was provided by Domain Associates, a San Diego venture firm that has supported Amylin Pharmaceuticals Inc., Biosite Inc. and NovaCardia.
Bradford Duft, chief executive officer of CoDa, is a patent attorney and was formerly vice president and general counsel at Amylin.
CoDa will use the $10 million for testing Nexagon’s ability to heal skin and eye wounds through phase one and two clinical trials.
CoDa’s technology was discovered by CoDa Therapeutics Ltd., a New Zealand company formed by inventors Dr. Colin Green, of the University of Auckland, and Dr. David Becker, of University College London. Clinical trials are conducted in New Zealand.
, Katie Weeks